Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

Vepdegestrant has been recognized with fast track designation by the FDA and is being co-developed by Arvinas and Pfizer. The ...

ASCO Data Shows New Therapy Delays Breast Cancer Progression and May Improve Quality of Life for Women with Hormone ...

The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates there will be over 35 million new ...

Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.

The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more ...

Arvinas, Inc. (NASDAQ: ARVN) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

with few discontinuations and low rates of gastrointestinal-related adverse events Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial ...

Those readouts include the VERITAC-2 trial of protein degrader vepdegestrant in second-line oestrogen receptor-positive metastatic breast cancer – the first key data from a drug Pfizer sees as ...